Komori
Presentation materials on financial results4884Kringle Pharma,Inc.Pharmaceuticals

Online Company Briefing for Individual Investors

The full-year forecast for the fiscal year ending September 2021 was revised, with an increase in projected revenue and significant reductions in operating loss, ordinary loss and net loss, reflecting lower research and development expenses and other factors. For the nine months ended June 2021, revenue was ¥117 million and operating loss was ¥304 million.

Worth reading
62In focus
Scored from 5 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
648
¥ millions (improvement in operating loss)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Presentation materials on financial resultsThird quarter of the fiscal year ending September 20216 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥117 million
Operating profit¥-304 million operating loss
Ordinary income¥-245 million ordinary loss
Net income¥-246 million net loss
Selling, general and administrative expenses¥422 million
Full-year earnings forecast
Net Sales
¥277 million
Cost of sales
¥73 million
Selling, General and Administrative Expenses
¥592 million
Research and development costs
¥409 million
Operating loss
¥-388 million
Ordinary loss
¥-328 million
Net loss for the period
¥-330 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Increase in revenue forecast¥71 million
    FactorsIncrease in the supply volume of HGF active pharmaceutical ingredient to クラリス社
  • Increase in cost of sales forecast¥29 million
  • Reduction in SG&A expense forecast¥-606 million
    FactorsDecrease in R&D expenses
  • Reduction in research and development expense forecast¥-588 million
    FactorsDelay in trials related to HGF manufacturing development and streamlining of trial items
  • Improvement in operating loss¥648 million
  • Improvement in ordinary loss¥686 million
  • Improvement in net loss¥686 million
New initiatives
  • Establishment of a Quality Assurance Department and a Corporate Strategy Office
  • Supply of HGF active pharmaceutical ingredient to クラリス・バイオセラピューティクス社 and development in the ophthalmology field
  • Development and establishment of manufacturing capabilities for the Phase III trial for the acute phase of spinal cord injury and in-house approval acquisition
Key KPIsA metric the company considers important as a management benchmark.
  • Target number of subjects in the Phase III trial for the acute phase of spinal cord injury25 cases
  • Target number of subjects in the Phase II ALS trial48 cases
  • Number of patients in Japan with acute spinal cord injury5,000 People/year
  • Number of ALS patients in Japan9,800 people
  • Number of employees11 People
Financial targets
Equity ratio
Actual results97.6 %
Market Size / Share
  • HGF protein formulation for the acute phase of spinal cord injuryJapan: up to ¥10 billion; overseas: up to ¥50 billion
  • HGF protein formulation for ALSJapan: up to ¥20 billion; overseas: up to ¥100 billion
Number of employees
Number of Employees11 People
Reference dateEnd of July 2021
Contents of this document
ItemDetails
Document typePresentation materials on financial results
Fiscal Period CoveredThird quarter of the fiscal year ending September 2021
Net Sales¥117 million
Operating profit¥-304 million (operating loss)
Ordinary income¥-245 million (ordinary loss)
Net income¥-246 million (net loss)
Selling, general and administrative expenses¥422 million
Full-year earnings forecastNet Sales ¥277 million / Cost of sales ¥73 million / Selling, General and Administrative Expenses ¥592 million / Research and development costs ¥409 million / Operating loss ¥-388 million / Ordinary loss ¥-328 million / Net loss for the period ¥-330 million
Breakdown of Factors Affecting the ChangeItem Increase in revenue forecast / Amount ¥71 million / Factors Increase in the supply volume of HGF active pharmaceutical ingredient to クラリス社, Item Increase in cost of sales forecast / Amount ¥29 million, Item Reduction in SG&A expense forecast / Amount ¥-606 million / Factors Decrease in R&D expenses, Item Reduction in research and development expense forecast / Amount ¥-588 million / Factors Delay in trials related to HGF manufacturing development and streamlining of trial items, Item Improvement in operating loss / Amount ¥648 million, Item Improvement in ordinary loss / Amount ¥686 million, Item Improvement in net loss / Amount ¥686 million
Key KPIsIndicator name Target number of subjects in the Phase III trial for the acute phase of spinal cord injury / Value 25 cases / Year on year against the same period last year Not disclosed, Indicator name Target number of subjects in the Phase II ALS trial / Value 48 cases / Year on year against the same period last year Not disclosed, Indicator name Number of patients in Japan with acute spinal cord injury / Value 5,000 People/year / Year on year against the same period last year Not disclosed, Indicator name Number of ALS patients in Japan / Value 9,800 people / Year on year against the same period last year Not disclosed, Indicator name Number of employees / Value 11 People / Year on year against the same period last year Not disclosed
Number of employeesNumber of Employees 11 People / Reference date End of July 2021 / Changes during the period and hiring plan Not disclosed
Financial targetsEquity ratio Actual results 97.6 %
Market Size / ShareSubject HGF protein formulation for the acute phase of spinal cord injury / Market Size Japan: up to ¥10 billion; overseas: up to ¥50 billion, Subject HGF protein formulation for ALS / Market Size Japan: up to ¥20 billion; overseas: up to ¥100 billion
New initiativesEstablishment of a Quality Assurance Department and a Corporate Strategy Office, Supply of HGF active pharmaceutical ingredient to クラリス・バイオセラピューティクス社 and development in the ophthalmology field, Development and establishment of manufacturing capabilities for the Phase III trial for the acute phase of spinal cord injury and in-house approval acquisition
Items this document does not state (17)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The revenue forecast was raised due to an increase in the supply volume of HGF active pharmaceutical ingredient to クラリス社. Research and development expenses also decreased because trials related to HGF manufacturing development were delayed and the number of trial items was streamlined. The company states that this will not affect the approval application schedule for the acute phase of spinal cord injury.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Online Company Briefing for Individual Investors | Kringle Pharma,Inc. (4884) timely disclosure | Komori